FDA approves dupilumab for children with eosinophilic esophagitis

The FDA has approved the use of dupilumab for treating eosinophilic esophagitis in children aged 1 to 11 years who weigh at least 15 kg, according to a press release.
The approval expands the use of dupilumab (Dupixent; Regeneron, Sanofi) beyond adults and adolescents aged 12 years and older who weigh at least 40 kg.
Regeneron and Sanofi report that this approval came after an FDA Priority Review, indicating its potential for significant improvements in efficacy or safety in treating serious conditions.
Also, the companies say that dupilumab is now the first and only medicine approved in the

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart